Erschienen in:
01.10.2003 | Adis Drug Profile
Dutasteride
A Viewpoint by Gerald L. Andriole
verfasst von:
Gerald L. Andriole
Erschienen in:
Drugs & Aging
|
Ausgabe 12/2003
Einloggen, um Zugang zu erhalten
Excerpt
Dutasteride is the first dual inhibitor of 5α-reductase. 5α-Reductase inhibition by finasteride (which inhibits only the type II isoenzyme) is well recognised to effectively alter the long-term natural history of benign prostatic hyperplasia (BPH). Specifically, men treated with 5α-reductase inhibitors have experienced significant reductions (60–70%) in the 4-year incidence of BPH-related surgery and acute urinary retention. Other medical treatments for BPH (such as α1-receptor blockers) seem to ameliorate the symptoms associated with BPH, but have less convincingly demonstrated an ability to reduce the incidence of BPH-related surgery or of acute urinary retention, as reported in the recently completed 4-year National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)-funded Medical Therapy of Prostatic Symptoms (MTOPS) trial. …
